SOURCE: Curidium Medica PLC

October 31, 2007 03:03 ET

Curidium Medica PLC announces Presentation at Conference

London--(Marketwire - October 31, 2007) -

               Curidium Medica plc ("Curidium" or the "Company")

                        9TH ANNUAL HEALTHCARE CONFERENCE
                       -Presentation to be Webcast Live-

London, UK, 31 October 2007, Curidium Medica plc, (LSE: CUR) the personalized
medicine company focused on bringing the right drug to the right patient, today
announced that Gosse B. Bruinsma M.D., Executive Chairman, will be presenting at
the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York,
New York, USA.  The presentation is scheduled at 4:25 pm Eastern time on
Tuesday, 6 November 2007 in the New York Palace Hotel. Dr. Bruinsma's
presentation will be webcast and is accessible remotely by persons wishing to
follow the presentation live and will be archived for 90 days; for access please


For further information, please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Chairman, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics

Notes to Editors

Curidium Medica

Curidium is a personalized medicine company identifying targeted medicines and
companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted
in the identification of a blood diagnostic test, PsychINDxTM, which classifies
patients with schizophrenia/bipolar disorder into four subgroups. PsychINDxTM
may have the potential to improve the treatment of patients with schizophrenia/
bipolar disorder.

Many chronic human diseases are heterogeneous and their patient populations
consist of mixed subgroups. Through the use of its proprietary analysis tool,
Homomatrix(R), Curidium aims to reveal different patient subgroups characterized
by distinct underlying disease mechanisms potentially leading to the
identification of:

 1. Diagnostics for better identification and treatment within heterogeneous
    disease populations.
 2. Improved therapies identified through novel drug targets.
 3. Personalized medicines using companion diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in
a variety of therapeutic areas. Further information on Curidium can be found at
the Company's website:

Curidium Medica plc (c) 2002-2007. All rights reserved.
Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.
Email: Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791

                      This information is provided by RNS
            The company news service from the London Stock Exchange